Fig. 4: miR-17-20a targets RCAN3 in ischemic endothelial cells and macrophages. | Communications Medicine

Fig. 4: miR-17-20a targets RCAN3 in ischemic endothelial cells and macrophages.

From: Inhibiting anti-angiogenic VEGF165b activates a miR-17-20a-Calcipressin-3 pathway that revascularizes ischemic muscle in peripheral artery disease

Fig. 4

qPCR of RCAN3 expression in a IgG- (blue bars) or V165b-Ab-treated (pink bars) ischemic muscle. n = 5. Unpaired t-test. b IgG- (blue bars) or V165b-Ab-treated (pink bars) HSS-SkMVECs. n = 5. Unpaired t-test. c IgG- (blue bars) or V165b-Ab-treated (pink bars) HSS-HUVECs. n = 6. Unpaired t-test. d IgG- (blue bars) or V165b-Ab-treated (pink bars) HSS-BMDMs. n = 6. Unpaired t-test. P < 0.05 significant. e 3’ UTR luciferase assay in HEK293 cells transfected with RCAN3 3’UTR luciferase plasmid followed by transfection with Neg-Mim (blue bars), miR-17-Mim (yellow bars), or miR-20a-Mim (pink bars). n = 6. One-way ANOVA with Dunnett’s post-test. f qPCR analysis of miR-17 (unpaired t-test with Welch’s correction), miR-20a, and RCAN3 Ct values in Ago2-IP fractions from normal (blue bars) and HSS (pink bars) HUVECs. n = 4. Unpaired t-test. g qPCR analysis (Ct values) of miR-17, miR-20a, and RCAN3 expression in RCAN3-IP fractions from normal (blue bars) and HSS (pink bars) BMDMs. n = 4. Unpaired t-test. h, i qPCR of RCAN3-expression in h HSS-HUVECs and, i HSS-BMDMs transfected with negative inhibitor (Neg-Inh, blue bars), miR-17 inhibitor (miR-17-Inh, yellow bars) or miR-20a inhibitor (miR-20a Inh, pink bars). n = 6. Unpaired t-test. Outliers were removed by performing the Grubbs test. P < 0.05 significant. Data from the biological replicates are presented as mean  ±  standard error.

Back to article page